Articles tagged with Ovarian Cancer
A phase III clinical trial found that taxane maintenance therapy did not significantly improve overall survival for women with advanced ovarian, peritoneal, and tubal cancers. The treatment resulted in significant gastrointestinal and neurological adverse events.
Wistar scientists have identified a novel therapeutic approach that inhibits the gene KDM5A, which improves immune cell infiltration and attack on tumors. This approach has shown promising results in both in vitro and in vivo studies, including reduced tumor burden and improved survival rates in mice with ovarian cancer.
Researchers from Bern and Geneva universities will receive $878,000 in funding to investigate mechanisms of resistance to PARPi inhibitors in BRCA-mutated ovarian cancer. The goal is to develop new targeted therapies to improve survival rates for patients with drug-resistant ovarian cancer.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
A new nanosensor platform uses machine learning to analyze spectral signatures of carbon nanotubes for early detection of ovarian cancer. The approach detects biomarkers and recognizes the cancer itself, offering a promising alternative to traditional methods.
Researchers identified OR2H1 as an effective target for CAR T cells in solid tumors, inhibiting growth in lung and ovarian cancer. The study suggests that targeting this protein could lead to the development of new CAR T therapies for a wide variety of patients with solid tumors.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...
Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.
Researchers developed a bioinformatics platform called REFLECT to predict optimal combination therapies based on co-occurring tumor alterations. The tool selected combinations that resulted in improved patient outcomes across pre-clinical and clinical studies, leading to increased durable responses.
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
A new study reveals funding for fertility preservation policies varies across the UK, with Scotland offering the most inclusive approach. The study highlights the need for standardization of policies to ensure equal access to care for patients.
The ATHENA-MONO trial shows significant improvements in progression-free survival for patients with advanced ovarian cancer treated with Rubraca as maintenance therapy. Benefit was observed across all patients, including those with homologous recombination deficiency and BRCA mutant tumors.
The Victoria's Secret Global Fund for Women's Cancers has awarded five female researchers for their groundbreaking work on breast and gynecologic cancers. The recipients will receive a $100,000 honorarium and be invited to participate in a broader women's cancers grant program.
Researchers create detailed 'atlas' of fallopian tube cells to better understand fertility and disease. The study identifies 10 epithelial cell subtypes and reveals new insights into ovarian cancer origins.
A new study published in Radiology has found that ultrasound images can effectively classify adnexal lesions into classic and non-classic categories, with a sensitivity of 92.5% for diagnosing malignancy. The classic versus non-classic approach could help radiologists quickly assess lesions and avoid unnecessary surgery.
The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
Researchers at University of Queensland have identified a genetic basis for the increased risk of epithelial ovarian cancer in women with endometriosis. The study found genes that could be targeted to treat both conditions, increasing understanding and treatment options.
A new study found that nearly one-third of older adult female survivors of colorectal, endometrial, and ovarian cancer experience quality-of-life-impacting challenges with physical activity due to chronic lower extremity lymphedema. The researchers urge the medical community to include regular lymphedema assessments in survivorship care.
A meta-analysis of over 3,000 studies found that women with one ovary have a 30% lower chance of becoming pregnant and giving birth after IVF. The study suggests that surgical removal of an ovary has an adverse effect on fertility.
Researchers created implantable beads that produce high concentrations of interleukin-2, a natural compound activating white blood cells to fight cancer. The treatment eradicated ovarian and colorectal cancer in mice within six days, paving the way for human clinical trials later this year.
Researchers at the University of Helsinki found that a cellular stress state predicts a poor chemotherapy response in ovarian cancer patients. High-stress tumours with an inflammatory microenvironment may resist chemotherapy, making combination therapies a potential solution.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
A new symptom management approach, WRITE Symptoms, guides patients to reflect on their symptoms and develop strategies for addressing target symptoms. Both nurse-led and self-directed versions of the tool improved women's sense of control over their symptoms after eight weeks.
Researchers found trametinib to significantly improve progression-free survival and objective response rate in low-grade serous ovarian carcinoma. The median PFS was 13 months, while the ORR was 26%.
A clinical trial found that trametinib significantly slowed ovarian cancer progression by 13 months and increased treatment response by fourfold compared to standard care. The drug showed promise as a new standard of care for low-grade serous ovarian cancer, a common but difficult-to-treat form of the disease.
The CHAMPS program, a multi-year quality improvement initiative in Mississippi, increased breastfeeding rates by 10 percentage points overall, with significant gains among Black mother-baby dyads. Rooming-in practices also improved, leading to reduced infant mortality and morbidity.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
Researchers have identified nine new factors involved in DNA repair, a critical process for human cell health. The findings can help develop new cancer drugs and improve existing therapies.
Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants support promising projects that aim to push cancer care forward. Researchers are working on various innovative projects, including a digital literacy training program for community health workers an...
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
Researchers have discovered that ovarian cancer begins with cancerous lesions in the fallopian tube linings of women with BRCA-1 mutations. The study's findings hold promise for predicting which women will develop ovarian cancer years or decades in advance, allowing for early detection and prevention strategies.
A study of over 200,500 women found an increased risk of death in younger pre-menopausal women when ovaries and fallopian tubes were removed during surgery. In contrast, the procedure is safer for older post-menopausal women, whose ovaries have already stopped producing estrogen.
Researchers at Hokkaido University analyzed hundreds of women with ovarian granulosa cell tumors to improve understanding of the disease progression and response to therapy. They found that early-stage tumors rarely spread beyond the ovaries, and fertility-sparing surgery may be considered for younger patients.
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
Researchers at The Wistar Institute have identified genes that help ovarian cancer evade the immune system. These findings could lead to more effective immunotherapy for ovarian and other types of cancer.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers at the University of Copenhagen have discovered that the BRCA2 gene requires a specific enzyme, PP2A-B56, to repair DNA damage. This finding may pave the way for more targeted treatment of cancer patients with certain mutations.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Researchers found that microscopic defects in healthy cell alignment can slow down tumor cell invasion. The study used an experimental model to show how topological defects affect the rate of tumor cell invasion, with certain defects causing cancer cells to pass through the barrier more slowly.
Researchers identified mono(ADP-ribose) and NMNAT-2 as potential biomarkers for ovarian cancers, enabling clinicians to determine which patients may respond well or poorly to treatment. The discovery also highlights a selective advantage that can be exploited to inhibit cancer growth.
Researchers have discovered a new group of patients who are likely to benefit from PARP inhibitor therapy, which has shown unprecedented success in treating BRCA1/2 mutated cancers. The study identified tumours with epigenetic marks that silenced the RAD51C gene, making them sensitive to PARP inhibitors.
Mayo Clinic researchers used advanced imaging technology to visualize the BRCA1-BARD1 protein complex and its interaction with chromatin. The study provides new insights into how BRCA1-BARD1 functions, which could lead to improved cancer prevention efforts and drug development.
Researchers at Texas A&M University have developed an organ-on-a-chip that models the interaction between platelets and ovarian cancer tumors, revealing a crucial genetic signaling pathway. This breakthrough technology has potential applications in observing how cancer cells interact with blood vessels and testing novel treatments.
A world-first AI study will map genetic and physical risks of ovarian cancer based on UK Biobank data. The project aims to identify biomarkers for early detection and improve survival rates.
Ovarian cancer is the most lethal gynaecological cancer with an absence of screening programmes, leading to late diagnosis and poor prognosis. Despite targeted therapies, personalized medicine remains a challenge due to inconsistent symptoms and resistance to chemotherapy.
The company's 3D Predict assay has been validated for predicting responses to temozolomide in glioblastoma patients, with predictive accuracy comparable to its previous results in ovarian cancer. The test identifies future responders and non-responders, enabling personalized treatment strategies.
A new study published in Proceedings of the National Academy of Sciences suggests that surgery should precede chemotherapy for certain patients with ovarian cancer. The research used a mathematical model to examine treatment outcomes and found that complete debulking surgery followed by chemotherapy provides better results. For patient...
A new radiopharmaceutical has been developed to treat ovarian cancer, dramatically limiting tumor growth and decreasing tumor mass. The treatment, which can be produced in just 25 minutes at low cost, shows promise as an efficient alternative to existing methods.
A Penn-developed odor test using AI and machine learning distinguishes between cancer cells and benign tumors in blood samples. The tool achieves high accuracy rates for detecting ovarian and pancreatic cancers, showing promise as a non-invasive screening approach.
Researchers from NUS Cancer Science Institute have discovered a link between high levels of DNA repair protein RAD51 and platinum chemotherapy resistance in ovarian cancer patients. This finding could help identify patients who may require novel immunotherapy approaches to improve treatment outcomes.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
A large-scale trial of annual screening for ovarian cancer found that neither method reduced deaths from the disease, contradicting expectations. Early detection strategies detected cancers earlier, but this did not translate into saving lives.
A study published in Nature Communications found that rucaparib is effective in treating ovarian cancers with inherited or somatic mutations in DNA repair genes. The drug targets the Achilles heel of cancers with defects in DNA repair, outperforming chemotherapy in early treatment stages.